CR20190530A - Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue - Google Patents

Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue

Info

Publication number
CR20190530A
CR20190530A CR20190530A CR20190530A CR20190530A CR 20190530 A CR20190530 A CR 20190530A CR 20190530 A CR20190530 A CR 20190530A CR 20190530 A CR20190530 A CR 20190530A CR 20190530 A CR20190530 A CR 20190530A
Authority
CR
Costa Rica
Prior art keywords
dengue viral
compounds
indoline derivatives
viral replication
substituted indoline
Prior art date
Application number
CR20190530A
Other languages
English (en)
Inventor
Jean-François Bonfanti
Dorothée Alice Marie-Eve Bardiot
Jérôme Michel Claude Fortin
Guillaume Jean Maurice Mercey
Arnaud Didier M Marchand
Bart Rudolf Romanie Kesteleyn
Erwin Coesemans
Pierre Jean-Marie Bernard Raboisson
Original Assignee
Janssen Pharmaceuticals Inc
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Univ Leuven Kath filed Critical Janssen Pharmaceuticals Inc
Publication of CR20190530A publication Critical patent/CR20190530A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a derivados de indolina sustituidos, a métodos para prevenir o tratar infecciones virales por dengue mediante el uso de dichos compuestos y también se refiere a dichos compuestos para su uso como medicamento, más preferentemente, para su uso como medicamento para tratar o prevenir infecciones virales por dengue. La presente invención se refiere además a composiciones farmacéuticas o preparados combinados de los compuestos, a las composiciones o preparados para su uso como un medicamento, más preferentemente para la prevención o el tratamiento de infecciones virales por dengue. La invención también se refiere a procesos para la preparación de los compuestos.
CR20190530A 2017-05-22 2018-05-18 Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue CR20190530A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17172237 2017-05-22
PCT/EP2018/063028 WO2018215315A1 (en) 2017-05-22 2018-05-18 Substituted indoline derivatives as dengue viral replication inhibitors

Publications (1)

Publication Number Publication Date
CR20190530A true CR20190530A (es) 2020-01-24

Family

ID=58745157

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190530A CR20190530A (es) 2017-05-22 2018-05-18 Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue

Country Status (25)

Country Link
US (2) US11407715B2 (es)
EP (1) EP3630723B1 (es)
JP (1) JP7203764B2 (es)
KR (1) KR102625988B1 (es)
CN (1) CN110691773B (es)
AR (1) AR111878A1 (es)
AU (1) AU2018274100B2 (es)
BR (1) BR112019024195A2 (es)
CA (1) CA3060583C (es)
CL (1) CL2019003294A1 (es)
CO (1) CO2019012035A2 (es)
CR (1) CR20190530A (es)
EA (1) EA201992782A1 (es)
EC (1) ECSP19083640A (es)
ES (1) ES2929667T3 (es)
IL (1) IL270726B2 (es)
MA (1) MA48943A (es)
MX (1) MX2019013893A (es)
NI (1) NI201900119A (es)
PE (1) PE20200604A1 (es)
PH (1) PH12019502559A1 (es)
TW (1) TWI758480B (es)
UA (1) UA125407C2 (es)
UY (1) UY37742A (es)
WO (1) WO2018215315A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
SG11201808270PA (en) 2016-03-31 2018-10-30 Janssen Pharmaceuticals Inc Substituted indoline derivatives as dengue viral replication inhibitors
SI3436435T1 (sl) 2016-03-31 2021-08-31 Janssen Pharmaceuticals, Inc. Substituirani derivati indolina kot zaviralci replikacije virusa denga
JP7007290B2 (ja) 2016-04-01 2022-01-24 ヤンセン ファーマシューティカルズ,インコーポレーテッド デングウイルス複製阻害剤としての置換インドール化合物誘導体
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
IL270727B2 (en) 2017-05-22 2023-03-01 Janssen Pharmaceuticals Inc Transduced indulin derivatives as inhibitors of dengue virus replication

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021559A1 (en) 1997-10-27 1999-05-06 Eli Lilly And Company MORPHOLINO-N-ETHYL ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
JP2005520795A (ja) 2001-12-12 2005-07-14 コンフォーマ・セラピューティクス・コーポレイション Hsp90阻害活性を有するプリン類似体
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
CN101103026A (zh) 2005-01-14 2008-01-09 健亚生物科技公司 用于治疗病毒感染的吲哚衍生物
CA2597213A1 (en) 2005-02-09 2006-09-14 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
BRPI0909985A2 (pt) 2008-06-03 2015-08-25 Siga Technologies Inc Composição farmacêutica e método para o tratamento ou profilaxia de uma infecção viral ou doença associada à mesma
US8143259B2 (en) * 2008-08-19 2012-03-27 Janssen Pharmaceutica, Nv Cold menthol receptor antagonists
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
WO2010091413A1 (en) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
US7948798B1 (en) 2009-07-22 2011-05-24 Marvell International Ltd. Mixed multi-level cell and single level cell storage device
PT2523951E (pt) 2010-01-15 2015-09-14 Gilead Sciences Inc Inibidores de vírus flaviviridae
US20130023532A1 (en) 2010-03-26 2013-01-24 Casillas Linda N Indazolyl-pyrimidines as kinase inhibitors
JP5716205B2 (ja) 2011-03-29 2015-05-13 学校法人日本大学 グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
EP2624519A4 (en) * 2011-09-30 2014-04-23 Huawei Tech Co Ltd NETWORKING METHOD AND DEVICE
GB201305376D0 (en) * 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
DK3060547T3 (en) 2013-10-23 2018-01-15 Janssen Sciences Ireland Uc CARBOXAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATMENT OF HEPATITS B
EP3988549A1 (en) 2014-01-31 2022-04-27 Bristol-Myers Squibb Company Macrocycles with heterocyclic p2' groups as factor xia inhibitors
RS58461B1 (sr) * 2014-10-01 2019-04-30 Janssen Pharmaceuticals Inc Mono- ili di-supstituisani derivati indola kao inhibitori replikacije virusa denge
NO2721243T3 (es) 2014-10-01 2018-10-20
CA2958022A1 (en) 2014-10-01 2016-04-07 Janssen Pharmaceuticals, Inc Mono- or di-substituted indoles as dengue viral replication inhibitors
JOP20150335B1 (ar) 2015-01-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PT3370698T (pt) 2015-11-03 2022-03-02 Zoetis Services Llc Compósitos de polímero sol-gel e utilizações dos mesmos
SI3436435T1 (sl) 2016-03-31 2021-08-31 Janssen Pharmaceuticals, Inc. Substituirani derivati indolina kot zaviralci replikacije virusa denga
CN109715613B (zh) 2016-03-31 2021-07-30 武田药品工业株式会社 杂环化合物
SG11201808270PA (en) * 2016-03-31 2018-10-30 Janssen Pharmaceuticals Inc Substituted indoline derivatives as dengue viral replication inhibitors
WO2017167832A1 (en) 2016-04-01 2017-10-05 Basf Se Bicyclic compounds
JOP20170069B1 (ar) * 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CA3018986A1 (en) 2016-04-01 2017-10-05 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
CR20210084A (es) 2016-04-01 2021-03-26 Amgen Inc Receptores quiméricos y métodos de uso de los mismos (divisional 2018-0480)
CN109328074A (zh) 2016-04-01 2019-02-12 凯德药业股份有限公司 嵌合抗原和t细胞受体及使用的方法
JP7007290B2 (ja) 2016-04-01 2022-01-24 ヤンセン ファーマシューティカルズ,インコーポレーテッド デングウイルス複製阻害剤としての置換インドール化合物誘導体
MY201207A (en) 2016-04-01 2024-02-09 Amgen Inc Chimeric receptors to flt3 and methods of use thereof
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
IL270727B2 (en) 2017-05-22 2023-03-01 Janssen Pharmaceuticals Inc Transduced indulin derivatives as inhibitors of dengue virus replication

Also Published As

Publication number Publication date
CA3060583A1 (en) 2018-11-29
PE20200604A1 (es) 2020-03-10
CN110691773A (zh) 2020-01-14
EA201992782A1 (ru) 2020-03-24
KR102625988B1 (ko) 2024-01-16
CA3060583C (en) 2024-06-04
EP3630723B1 (en) 2022-08-24
US20220340522A1 (en) 2022-10-27
CL2019003294A1 (es) 2020-03-20
UA125407C2 (uk) 2022-03-02
WO2018215315A1 (en) 2018-11-29
MA48943A (fr) 2021-04-28
US11795149B2 (en) 2023-10-24
NI201900119A (es) 2020-03-23
CO2019012035A2 (es) 2020-01-17
IL270726A (en) 2020-01-30
AU2018274100B2 (en) 2022-06-23
PH12019502559A1 (en) 2021-01-25
IL270726B2 (en) 2023-05-01
BR112019024195A2 (pt) 2020-06-23
US11407715B2 (en) 2022-08-09
IL270726B1 (en) 2023-01-01
JP7203764B2 (ja) 2023-01-13
TWI758480B (zh) 2022-03-21
AU2018274100A1 (en) 2019-11-21
UY37742A (es) 2018-11-30
EP3630723A1 (en) 2020-04-08
MX2019013893A (es) 2020-01-20
KR20200009027A (ko) 2020-01-29
AR111878A1 (es) 2019-08-28
ECSP19083640A (es) 2019-11-30
CN110691773B (zh) 2023-06-23
US20200255376A1 (en) 2020-08-13
ES2929667T3 (es) 2022-11-30
JP2020520946A (ja) 2020-07-16
TW201908291A (zh) 2019-03-01

Similar Documents

Publication Publication Date Title
PH12019502577A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
JOP20210109A1 (ar) مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12018502077A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12018502026A1 (en) Substituted indole compound derivatives as dengue viral replication inhibitors
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12018502016A1 (en) Substituted indole derivatives as dengue viral replication inhibitors
PH12018502015A1 (en) Substituted indole derivatives as dengue viral replication inhibitors
PH12019502559A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12018500569A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
PH12018500576A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
PH12017501272A1 (en) Indole derivatives as dengue viral replication inhibitors
PH12017500571A1 (en) Mono-or di-substituted indole derivatives as dengue viral replication inhibitors
PH12017500503A1 (en) Mono- or di-substituted indoles as dengue viral replication inhibitors
MY185672A (en) Mono-or di-substituted indole derivatives as dengue viral replication inhibitors
MY197383A (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors